Liver Cirrhosis Clinical Trial
Official title:
Anticoagulation for Development of Further Decompensation and Survival in Advanced Cirrhosis After Transjugular Intrahepatic Portosystemic Shunt: a Multicenter Randomized Controlled Study
Recent studies demonstrated that liver cirrhosis was associated with a hypercoagulability state. Besides, bacterial translocation plays an important role in the pathogenesis and complications in patients with decompensated cirrhosis, including infections as well as hepatic encephalopathy and hepatorenal syndrome. A recent prospective study in a group of 70 patients with liver cirrhosis (Child B and C stages up to 10 points) who were randomized to receive enoxaparin for a year (n = 34) vs no intervention (n = 36) showed that anticoagulant treatment with enoxaparin is safe and effective, significantly reducing risk of PVT development and liver decompensation, markedly improving overall survival. This study provides exciting preliminary data regarding the potential use of prophylactic anticoagulation in improving clinical outcomes in cirrhosis, beyond the prevention of portal vein thrombosis. This study suggested that the effect was partly due to a direct effect of reducing BT and levels of proinflammatory cytokines. However, this study included few patients, was not double blind, and did not have a placebo group. Therefore, despite the spectacular results, the use of prophylactic anticoagulant therapy has not become routine practice in patients with cirrhosis and more studies are needed to assess the potential usefulness of anticoagulation in improving the prognosis of liver cirrhosis. Transjugular intrahepatic portosystemic shunts (TIPS) are now routinely used to treat the complications of portal hypertension, such as variceal bleeding and refractory ascites. TIPS is the most effective method to prevent rebleeding, however, it is burdened with increased risk of hepatic encephalopathy and deterioration of liver function in patients with advanced cirrhosis. Notably, TIPS can not only relieve portal pressure but also can redirect the portal blood flow through the shunt directly into the systemic circulation which can cause systemic hemodynamic changes. Given the preliminary data suggesting a beneficial effect of prophylactic anticoagulation with LMWH in cirrhotic patients, this multicenter randomized controlled study attempts to demonstrate the effect of long term LMWH therapy after TIPS on survival in cirrhotic patients with variceal bleeding.
Status | Recruiting |
Enrollment | 254 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | All inclusion criteria must be met at the time of screening: - Signed informed consent. - Male or female patients with an age of 18 to 75 years - Liver cirrhosis. - History of variceal bleeding > 5 days - Presence of ascites - Successful TIPS - Use of Viatorr stent - Child-Pugh score within B7-C13 - Bilirubin level of 3 mg/dL or less (51.3 umol/L) Patients who meet the following criteria at the time of screening will be excluded: - Hepatocellular carcinoma or other intrahepatic/extrahepatic cancers. - Spontaneous overt hepatic encephalopathy. - Previous or current portal venous system thrombosis. - Budd-Chiari syndrome. - Known coagulation disorder besides liver cirrhosis. - Severe thrombocytopenia <15,000 platelets/dl. - Peptic ulcer disease in the last 6 months. - Unstable angina or myocardial infarction (MI) within the past 6 months before randomization. - Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted). - Uncontrolled hypertension. - Prior liver transplantation or candidates for liver transplantation. - History of shunting surgery or TIPS before randomization. - Pregnancy or breastfeeding - Poor compliance - Participation in another clinical trial - Close affiliation with the investigational site. |
Country | Name | City | State |
---|---|---|---|
China | The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
China | Nanfang Hospital Affiliated to Southern Medical University | Guanzhou | Guangdong |
China | The First Affiliated Hospital of Zhejiang University | Hangzhou | Zhejiang |
China | Provincial Hospital Affiliated to Shandong University | Jinan | Shandong |
China | The Second Affiliated Hospital of Kunming Medical University | Kunming | Yunnan |
China | The first affiliated hospital of Nanchang university | Nanchang | Jiangxi |
China | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nanjing | Jiangsu |
China | The First Affiliated Hospital of Xinjiang Medical University | Ürümqi | Xinjiang |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi |
China | The First Affiliated Hospital, Air Force Medical University | Xi'an | Shaanxi |
China | Xi'an International Medical Center Hospital | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Air Force Military Medical University, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Transplant-free survival | 2 years | ||
Secondary | Number of participants with all-cause rebleeding | 2 years | ||
Secondary | Number of participants with overt hepatic encephalopathy | 2 years | ||
Secondary | Number of participants with recurrent or worsening ascites | Perform two or more evacuative paracentesis in the following six months | 2 years | |
Secondary | Number of participants with shunt dysfunction | 2 years | ||
Secondary | Effect of anticoagulation on liver function estimated by the Child-Pugh and the model for end-stage liver disease scores | 2 years | ||
Secondary | Echocardiography findings | 2 years | ||
Secondary | Serum levels of bacterial translocation biomarkers and proinflammatory cytokines | 2 years | ||
Secondary | Security of anticoagulation in patients with liver cirrhosis | Number of adverse events and adverse reactions in each arm of study. History and clinical evaluation of bleeding and monitoring of hematocrit. | 2 years | |
Secondary | Compliance | Record of unused packaging and information about compliance in a patient diary | 2 years | |
Secondary | Score of Health Related Quality of Life questionnaire,for example, SF-36 | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04533932 -
Endosonographic Shear Wave Elastography for Liver Stiffness
|
||
Not yet recruiting |
NCT06031740 -
A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids
|
N/A | |
Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
Not yet recruiting |
NCT06076330 -
Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension
|
N/A | |
Enrolling by invitation |
NCT05055713 -
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
|
N/A | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Not yet recruiting |
NCT05515861 -
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
|
N/A | |
Not yet recruiting |
NCT02710227 -
Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis
|
N/A | |
Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Active, not recruiting |
NCT02551250 -
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
|
||
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Terminated |
NCT02311985 -
Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial
|
N/A | |
Terminated |
NCT01937130 -
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
|
Phase 2 | |
Recruiting |
NCT01724697 -
Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01728688 -
Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01618890 -
Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding
|
Phase 3 | |
Recruiting |
NCT01728727 -
Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis
|
Phase 1/Phase 2 |